D.E. Shaw & Co
CADX

D.E. Shaw & Co’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

D.E. Shaw & Co’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-102,552
Closed -$928K – 4948
2013
Q4 		$928K Buy
102,552
+49,069
+92% +$354K ﹤0.01% 3241
2013
Q3 		$337K Sell
53,483
-104,262
-66% -$663K ﹤0.01% 3838
2013
Q2 		$1.08M Buy
+157,745
New +$1.1M ﹤0.01% 2648

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

D.E. Shaw & Co's CADX Position: Q1 2014 in Review

D.E. Shaw & Co sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 102,552 shares — an estimated $928K sold.

D.E. Shaw & Co first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $1.08M in Q2 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • D.E. Shaw & Co reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • D.E. Shaw & Co sold 102,552 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $928K.
  • D.E. Shaw & Co first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
  • D.E. Shaw & Co's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $1.08M in Q2 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on D.E. Shaw & Co's 13F filing for Q1 2014, filed 15 May 2014.